ABSTRACT
Melanocortin receptors (MCRs) are a family of G protein-coupled receptors that regulate important physiological functions. Yet, drug development targeting MCRs is hindered by potential side effects due to a lack of receptor subtype-selective ligands with bioavailability. Here, we report novel synthetic pathways to introduce Ψ and χ angle constraints at the C-terminus Trp position of the nonselective prototype tetrapeptide agonist Ac-His-d-Phe-Arg-Trp-NH2. With these conformational constraints, peptide 1 (Ac-His-d-Phe-Arg-Aia) shows improved selectivity at hMC1R, with an EC50 of 11.2 nM for hMC1R and at least 15-fold selectivity compared to other MCR subtypes. Peptide 3 (Ac-His-pCF3-d-Phe-Arg-Aia) is a potent and selective hMC4R agonist with an EC50 of 4.1 nM at hMC4R and at least ninefold selectivity. Molecular docking studies reveal that the Ψ and χ angle constraints force the C-terminal Aia residue to flip and interact with TM6 and TM7, a feature that we hypothesize leads to the receptor subtype selectivity.
Subject(s)
Melanocyte-Stimulating Hormones , Receptors, Melanocortin , Molecular Docking Simulation , Molecular Conformation , Structure-Activity Relationship , Receptor, Melanocortin, Type 4/metabolismABSTRACT
Melanoma skin cancer is the fastest growing cancer in the US [1]. A great need exists for improved formulations and mechanisms to prevent and protect human skin from cancers and other skin damage caused by sunlight exposure. Current efforts to prevent UV damage to human skin, which in many cases leads to melanoma and other skin cancers. The primordial melanocortin-1 receptor (MC1R) is involved in regulating skin pigmentation and hair color, which is a natural prevention from UV damage. The endogenous melanocortin agonists induce pigmentation and share a core pharmacophore sequence "His-Phe-Arg-Trp", and it was found that substitution of the Phe by D-Phe results in increasing melanocortin receptor potency. To improve the melanocortin 1 receptor (MC1R) selectivity a series of tetra-peptides with the moiety of Ac-Xaa-Yaa-Nle-Trp-NH2, and structural modifications to reduce electrostatic ligand-receptor interactions have been designed and synthesized. It is discovered that the tetrapeptide Ac-His-D-Phe(4-CF3)-Nle-Trp-NH2 resulted in a potent and selective hMC1R agonist at the hMC1R (EC50: 10â¯nM). Lizard anolis carolinensis pigmentation study shows very high potency in vivo. NMR studies revealed a reversed ß turn structure which led to the potency and selectivity towards the hMC1R.
Subject(s)
Melanocyte-Stimulating Hormones/chemistry , Melanocyte-Stimulating Hormones/pharmacology , Receptor, Melanocortin, Type 1/agonists , Skin Pigmentation/drug effects , Amino Acid Sequence , Animals , Cyclic AMP/metabolism , Humans , Lizards , Molecular Docking Simulation , Receptor, Melanocortin, Type 1/metabolism , Structure-Activity RelationshipABSTRACT
Melanoma is a lethal form of skin cancer. Skin pigmentation, which is regulated by the melanocortin 1 receptor (MC1R), is an effective protection against melanoma. However, the endogenous MC1R agonists lack selectivity for the MC1R and thus can have side effects. The use of noncanonical amino acids in previous MC1R ligand development raises safety concerns. Here we report the development of the first potent and selective hMC1R agonist with only canonical amino acids. Using γ-MSH as a template, we developed a peptide, [Leu3, Leu7, Phe8]-γ-MSH-NH2 (compound 5), which is 16-fold selective for the hMC1R (EC50 = 4.5 nM) versus other melanocortin receptors. Conformational studies revealed a constrained conformation for this linear peptide. Molecular docking demonstrated a hydrophobic binding pocket for the melanocortin 1 receptor. In vivo pigmentation study shows high potency and short duration. [Leu3, Leu7, Phe8]-γ-MSH-NH2 is ideal for inducing short-term skin pigmentation without sun for melanoma prevention.
Subject(s)
Hypothalamic Hormones/pharmacology , Melanocyte-Stimulating Hormones/pharmacology , Receptor, Melanocortin, Type 1/agonists , Skin Pigmentation/drug effects , Animals , Drug Stability , HEK293 Cells , Half-Life , Humans , Hypothalamic Hormones/administration & dosage , Hypothalamic Hormones/chemical synthesis , Hypothalamic Hormones/pharmacokinetics , Iodine Radioisotopes , Ligands , Melanocyte-Stimulating Hormones/administration & dosage , Melanocyte-Stimulating Hormones/chemical synthesis , Melanocyte-Stimulating Hormones/pharmacokinetics , Molecular Conformation , Molecular Docking Simulation , Receptor, Melanocortin, Type 1/chemistry , Reptiles , alpha-MSH/administration & dosage , alpha-MSH/analogs & derivatives , alpha-MSH/chemical synthesis , alpha-MSH/pharmacokinetics , alpha-MSH/pharmacologyABSTRACT
In this issue of Expert Opinion on Investigational Drugs, several protein kinases families and pathways underlying cancer and other diseases are reviewed and several small molecule inhibitors that are in clinical trials are further described. Highlights of these reviews and drug evaluations are summarized in this editorial.